The “Deep Draw Container Forming Method” developed by Mystic Pharmaceuticals for packaging of intranasal drugs for use with its VersiDoser and VRx2 intranasal delivery systems has been awarded US Patent No. 7,963,089. Both delivery systems use the proprietary unit dose blister packaging. The VersiDoser uses liquid-filled blisters, while the VRx2 reconstitutes freeze … [Read more...] about Mystic Pharmaceuticals receives patent for intranasal drug packaging technology
News
Generex reboots buccal insulin spray development program
After receiving written guidance from the FDA in late May, says Generex, it has revised its development program for its Oral-lyn buccal insulin spray. A reorganized medical/regulatory group within the company will focus its efforts on providing information requested by the agency regarding the product's "preclinical, clinical, toxicology, manufacturing, and regulatory … [Read more...] about Generex reboots buccal insulin spray development program
BMJ article links Respimat inhaler to increased mortality
An article by Johns Hopkins researchers published in the BMJ, the British Medical Journal, suggests that patients using the Respimat tiotropium soft mist inhaler for the treatment of COPD are 52% more likely to die than those inhaling a placebo from a soft mist inhaler. "What we think is going on is that the mist inhaler is delivering a higher concentration of … [Read more...] about BMJ article links Respimat inhaler to increased mortality
Pfizer puts Sandwich site up for sale
The UK site where Pfizer has performed inhalation R&D is now on the market as "Discovery Park." The company announced the closing of the site, which employed 2400 people, in February 2011. Although a representative said, "The name Discovery Park reflects our hope that the site will continue, in part at least, to be a centre for research and development," the sales … [Read more...] about Pfizer puts Sandwich site up for sale
Teva begins shipping generic version of Nasacort AQ
According to Perrigo Company, which is partnered with Teva on a generic triamcinolone acetonide nasal spray, Teva has begun shipping the product. Perrigo developed the nasal spray, which is a generic equivalent of Sanofi's Nasacort AQ, and is manufacturing it. The US FDA approved the application for the product for the treatment of nasal symptoms resulting from … [Read more...] about Teva begins shipping generic version of Nasacort AQ
Hovione files patent for new DPI
Hovione has announced the filing of an international patent for its new XCaps dry powder inhaler. According to the company, the XCaps DPI is "a device which only requires two steps to inhalation and which only has two components plus a dust cover," and which it says can generate fine particle fractions greater than 70%. XCaps is available for license as part of … [Read more...] about Hovione files patent for new DPI
SPARC announces plans to launch new DPI
Sun Pharma Advanced Research Company (SPARC) has announced completion of Phase 3 studies for a new dry powder inhaler and its intention to launch a product based on the novel DPI in India by the end of the 2nd quarter of the fiscal year. In addition, the company said, it plans to file an IND in the US by the end of the fiscal year. The DPI delivers a dry powder … [Read more...] about SPARC announces plans to launch new DPI
Savara graduates from technology incubator
Dry powder inhalation drug developer Savara Pharmaceuticals has graduated from the Austin Techonology Incubator (ATI) Bioscience Incubator, according to ATI. Savara, which was founded in 2007, is preparing for Phase 1 trials of its lead candidate, an inhaled antibiotic. “A transition from the laboratory into the clinic represents a significant accomplishment and … [Read more...] about Savara graduates from technology incubator
Potential for intranasal vaccine to prevent diabetes
The Walter and Eliza Hall Institute (WEHI), Melbourne, Australia, has announced successful demonstration of proof of principle for a nasal spray vaccine to prevent type 1 diabetes. The research, conducted by scientists from WEHI and the Royal Melbourne Hospital, showed that the nasal spray suppress the body's immune response against insulin in humans. Because type … [Read more...] about Potential for intranasal vaccine to prevent diabetes
Insmed presents positive Phase 2 data for Arikace
At the European Cystic Fibrosis Conference in Hamburg, Germany, Insmed presented data showing that Arikace liposomal amikacin for inhalation improved lung function in CF patients over six cycles of treatment. Each cycle included 28 days in which patients received doses of Arikace, followed by 56 days off therapy, and the total period was 72 weeks. The product also … [Read more...] about Insmed presents positive Phase 2 data for Arikace